Bellicum Pharmaceuticals is a clinical stage biopharmaceutical company focused on discovering and developing novel cellular immunotherapies for various forms of cancer, including both hematological and solid tumors, as well as orphan inherited blood disorders.
BLCM has three product candidates in clinical development: BPX-501, an adjunct T-cell therapy product candidate being evaluated in Phase I/II clinical trials in children and adults following a T-depleted, haploidentical hematopoietic stem cell transplant (HSCT); BPX-601, a GoCAR-T product candidate in Phase I development for solid tumors expressing the prostate stem cell antigen; and BPX-701, a T cell receptors (TCR) product candidate in Phase I development for AML with future development potential for treatment of solid tumors expressing the preferentially-expressed antigen in melanoma.
BLCM has collaboration agreements with Adaptimmune Therapeutics plc to evaluate, develop, and commercialize T-cell therapies; Ospedale Pediatrico Bambino Gesú for the design and development of various T cell immunotherapies; and Academisch Ziekenhuis Leiden for research to discover and validate high-affinity TCR product candidates targeting various cancer-associated antigens.
Bellicum Pharmaceuticals, Inc. was founded in 2004 and is headquartered in Houston, Texas.
May 15, 2020
RegMed Investors’ (RMi) closing bell: ending it on a sector good note
May 13, 2020
RegMed Investors’ (RMi) closing bell: winners and losers depend on timing of entry and escape
May 13, 2020
RegMed Investors’ (RMi) pre-open: love the highs, not the lows and a number of goodbyes
May 12, 2020
RegMed Investors’ (RMi) closing bell: Staring at the abyss after viewing the sector’s rise
May 11, 2020
RegMed Investors’ (RMi) closing bell: markets get drained as the sector gains momentum
May 11, 2020
RegMed Investors’ (RMi) pre-open: which path forward, what’s over, around and bending any curve?
May 8, 2020
RegMed Investors’ (RMi) closing bell: fugly unemployment rates were priced into Friday’s market’s recovery
May 7, 2020
RegMed Investors’ (RMi) closing bell: Confidence perceived is not always value achieved
35 companies, 1 interpreter!
Insight, foresight and recommendation
Bellicum Pharmaceuticals (BCLM) - January '18 opened at $9.23, slipping to a low of $6.80 on 1/31 flowed by 2/1's $5.87 yet jumping to $6.60 by 2/16. After the KITE and JUNO acquisitions, many percieve that BLCM could be percieved as an appreciator in 2018 ... We do NEED to remember; the U.S. FDA placed a clinical hold on its lead product candidate BPX-501 that's being assessed as an adjunct T-cell therapy administered after haploidentical hematopoietic stem cell transplant. The hold reportedly stems from three cases of potentially treatment-related encephalopathy (abnormal brain function) that occurred during an ongoing trial. BLCM's shares were down 1/31/18 by 33.5% on heavy volume in response to this news.
buyMy motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.
My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.
Do you have an opinion you would like to share with us? We would like to hear from you.
Please e-mail us at hwm@regmedinvestors.com.
Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors
© 2026 RegMed Investors (regmedinvestors.com), all rights are reserved.
RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.
The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.
The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.